Weave (WEAV) Q2 2026 earnings review
Pivoting from Growth to Profitability
Weave delivered a quarter that looks strong on the surface but hides a fundamental shift in strategy. While Q2 revenue of $67.5M met expectations and operating margins expanded impressively to 4.7%, management quietly cut full-year revenue guidance by $2.5M at the midpoint. Simultaneously, they raised full-year operating profit guidance. This is a classic 'harvesting' pattern: the company is succeeding in upselling existing customers (payments, AI modules) and controlling costs, but is sacrificing top-line momentum. Revenue growth is now Decelerating, dropping from 17.4% in Q1 to 15.5% in Q2, with Q3 guidance implying a further slowdown to roughly 12.7%.
🐂 Bull Case
Non-GAAP operating income surged to $3.2M, up from essentially break-even a year ago. Free cash flow nearly doubled YoY to $8.7M, proving the business model can scale profitably.
The highly anticipated Omnichannel AI Receptionist, built on Google Cloud's Gemini, officially launched. This positions Weave to directly capture a share of healthcare practices' labor budgets.
🐻 Bear Case
Despite CEO quotes highlighting 'consistent growth', the hard numbers show a clear deceleration. The FY26 revenue guidance cut confirms that the core engine is slowing down.
The press release notably omitted Net Revenue Retention (NRR). Given that NRR was already at a tepid 92% in Q1, the lack of transparency alongside a guidance cut suggests underlying churn or delayed upsell traction.
⚖️ Verdict: ⚪
Neutral. The transition to a profitable, cash-generating business is commendable and executed well. However, the silent reduction in full-year revenue guidance contradicts the management's bullish narrative and signals that Weave is struggling to maintain its premium growth valuation.
Key Themes
Unexplained Revenue Guidance Cut Contradicts Narrative
The most critical takeaway from this report is what was not said. In Q1, management raised FY26 revenue guidance to $275-$278M. In Q2, despite beating the Q2 midpoint, they lowered the FY26 range to $273-$275M. This implies a significant deceleration in the second half of the year, directly contradicting the CEO's quote of 'consistent growth and improvement.' Investors must watch this Decelerating trend closely.
Omnichannel AI Receptionist Goes Live
Weave successfully launched its Omnichannel AI Receptionist, built on Google Cloud's Gemini Enterprise Agent Platform. This is a critical technological innovation. It handles complex workflows like appointment scheduling and call routing 24/7 across both voice and text. This directly addresses the severe healthcare labor shortage (a key Macro tailwind) and transitions Weave from simple communication software to a mission-critical operational asset.
Deepening Practice Management Integrations
Weave announced a new authorized integration with Elation Health and joined the athenahealth Marketplace (athenaOne, reaching 160,000+ providers). This expands Weave's Total Addressable Market (TAM) into primary care and larger specialty groups, paving the way for higher Average Selling Prices (ASP) and lower churn.
Payments Revenue Continues to Outpace Core
Management noted that the payments business 'accelerated at twice that pace' of total revenue (implying >31% YoY growth). As Weave shifts toward being a comprehensive financial solution for practices, this high-margin, sticky revenue stream remains the strongest lever for expanding wallet share.
Onboarding Margins Deteriorating Further
While subscription margins remain healthy (77.9%), the Onboarding segment continues to bleed cash. Q2 Onboarding gross margin fell to an alarming -239.8%, significantly worse than -149.1% a year ago. This suggests Weave is heavily subsidizing implementation costs to land new customers, a model that may hinder long-term profitability if retention doesn't hold up.
Silence on Net Revenue Retention (NRR)
In Q1, NRR sat at 92%, a metric management claimed had 'found the floor.' The Q2 earnings release completely omitted any update on NRR or Gross Revenue Retention (GRR). When a struggling metric disappears from the headline release during a quarter where guidance is cut, it is a glaring red flag for potential customer churn.
Macro Tailwinds: Healthcare Labor Shortage
Weave's core value proposition continues to benefit from a structural macro environment: a chronic shortage of front-office healthcare staff. By framing their AI as an 'always-on teammate,' they are successfully shifting their pricing conversations from software budgets to much larger labor budgets.
Other KPIs
Accelerating dramatically. Q2 FCF nearly doubled from $4.5 million in 25Q2. This marks a sharp rebound from the seasonal -$7.1 million outflow seen in Q1, proving the company's operating leverage is translating into genuine cash generation.
Stable and steadily improving. Expanded 30 basis points YoY. This was driven primarily by the core Subscription and Payment Processing segment, which boasts a robust 77.9% gross margin, effectively absorbing the deep losses from hardware and onboarding.
Guidance
Decelerating. The midpoint of $69.1M implies YoY growth of roughly 12.7% (compared to $61.3M in 25Q3). This is a noticeable step down from the 15.5% growth achieved in the current quarter.
Decelerating. Management cut the midpoint to $274.0M from the $276.5M guidance provided just one quarter ago. This reduction raises questions about the back-half momentum, especially regarding the monetization timeline of the new AI Receptionist.
Accelerating. Raised from the previous expectation of $10.5-$13.5M. This highlights management's strict focus on cost discipline and operating leverage, proving they can expand margins even as top-line expectations are tempered.
Key Questions
The Disconnect in Guidance
You cited 'consistent growth' and added record new locations, yet you lowered the midpoint of full-year revenue guidance by $2.5M. Specifically, what segment or product line is causing the back-half revenue weakness?
NRR Transparency
Net Revenue Retention was omitted from the press release after sitting at 92% in Q1. Did NRR slip further in Q2, and how is the initial churn trending in the rapidly expanding specialty medical segment?
Onboarding Subsidies
Onboarding gross margins collapsed further to -239.8%. How long do you anticipate heavily subsidizing implementation costs, and at what scale will this segment approach break-even?